Investor Relations Overview | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

we aspire to be the patient-preferred biotech leader. 

To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.

Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.

In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success. 




Based on UCB’s current assessment of the COVID-19 pandemic, UCB remains confident in the fundamental underlying demand for its products and its prospects for long-term growth. UCB will continue to closely follow evolving COVID-19 pandemic diligently to assess potential near- and mid-term challenges.

The figures of the guidance 2022 and 2025 as mentioned below were calculated on the same basis as the actual figures for 2021.


Upcoming Report

2022 Full-Year Results

More information closer to the date

2022 Revenue

€ 5.3 - 5.4 billion

based on continued core product growth and taking into account loss of exclusivity impacts


2022 adj. EBITDA 

21% - 22%

reflecting the Zogenix integration, the bimekizumab complete response letter in the US and the macro situation


2022 Core EPS

€ 3.70 - 4.00

based on an average of 189 million shares outstanding


2025 Revenue

at least € 6 billion

2025 adj. EBITDA

Low- to mid-thirties

2025 Improved ESG

rating performance


Contact UCB IR Team or a specific team member: